#USA #Clinical Trials #Life Sciences #CARY #SAS Viya

Revolutionizing Clinical Trials with SAS Clinical Acceleration

The advent of SAS Clinical Acceleration marks a significant milestone in the field of clinical trials, providing life sciences companies with the tools needed to navigate the complexities of modern drug development. As the healthcare industry evolves at an unprecedented pace, pharmaceutical and biotechnology firms find themselves under immense pressure to expedite drug development processes while adhering to strict global regulatory requirements. Recognizing these challenges, SAS has stepped up with a solution that leverages its powerful SAS Viya platform to enhance clinical analytics and streamline the path to market for new therapies.

In recent years, the influx of data from real-world sources, biomarker studies, and digital protocols has revolutionized clinical trial methods. However, these advancements come with their own set of complexities that legacy systems often struggle to manage. SAS Clinical Acceleration aims to address these complexities head-on by modernizing clinical trial processes and making them more efficient.

Key Features of SAS Clinical Acceleration

SAS Clinical Acceleration boasts a modular, cloud-native framework that facilitates comprehensive data management across various stages of clinical research. This solution allows clinical development teams to:

• - Manage and Analyze Data: Users can efficiently manage, analyze, and report clinical data in a validated environment, which promotes data integrity and credibility.
• - Reduce Submission Timelines: By consolidating information into a single repository, SAS Clinical Acceleration enables faster regulatory submissions, ultimately expediting the time it takes to bring new therapies to market.
• - Enhance Collaboration: The platform fosters improved collaboration among stakeholders, including sponsors, clinical research organizations, and regulatory agencies, ensuring a seamless workflow throughout the clinical development lifecycle.

Meeting Compliance Standards

Compliance with regulatory standards is paramount in the life sciences sector. SAS Clinical Acceleration addresses this critical need by supporting adherence to the FDA's Title 21 CFR Part 11 regulations, which include essential features such as audit trails, electronic signatures, and role-based permissions. Furthermore, the solution is compatible with CDISC standards, which are crucial for effective data management and submission.

Integration of Advanced Technologies

One of the standout features of SAS Clinical Acceleration is its built-in support for artificial intelligence and machine learning. The platform leverages generative AI tools, including large language models (LLMs) and digital twins, allowing organizations to harness the full potential of their data. This integration not only streamlines analytics but also enhances the overall quality of insights that can be gleaned from clinical trials.

The Impact on Clinical Development

According to Dr. Mark Lambrecht, Global Head of Health Care and Life Sciences at SAS, the financial ramifications of delays in therapy approvals can be astronomical, often costing millions while significantly impacting patient outcomes. SAS Clinical Acceleration aims to minimize these costly delays, making it a pivotal tool for life sciences organizations aiming to enhance their clinical analytics infrastructure.

Future enhancements to the platform will include workflow automation and expanded analytics capabilities, further improving the clinical trial process.

As SAS gears up to present this innovative solution at the PHUSE EU Connect conference in Hamburg, Germany, it signals a commitment to transforming drug development through cutting-edge technology. Attendees are invited to witness live demonstrations and engage with SAS experts, exploring how these advancements can address current industry challenges.

In conclusion, SAS Clinical Acceleration brings a fresh perspective and enhanced capabilities to the clinical trials landscape. By bridging the gap between complex data challenges and regulatory compliance, SAS is poised to facilitate a new era of drug development aimed at delivering life-saving therapies to patients more swiftly and efficiently than ever before.